📰 Aditxt News
Aditxt News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Aditxt. Real-time updates on events, politics, business and more.
April 25, 2024
Aditxt, Inc. (NASDAQ:ADTX – Get Free Report) saw a large increase in short interest in April. As of April 15th, there was short interest totalling 212,300 shares, an increase of 988.7% from the March 31st total of 19,500 shares. Approximately 10.8% of the company’s stock are sold short. Based on an average daily trading volume, […]
April 9, 2024
Halifax-based biopharmaceutical company Appili Therapeutics has agreed to be acquired by Virginia life sciences company Aditxt in a nearly $17-million CAD deal.
April 2, 2024
Shares of Aditxt, Inc. (ADTX) gained over 17% on Tuesday morning after the company agreed to buy Appili Therapeutics (APLIF) ADTX is currently trading at $3.7233, up $0.
January 8, 2024
By Chris Wack Aditxt has acquired MDNA Life Sciences for consideration of 50,000 shares of Aditxt stock, warrants to buy 50,000 Aditxt shares, 5,000 shares...
January 2, 2024
By Chris Wack Aditxt shares were down 24% to $5.05 in premarket trading after the company on Friday entered into definitive agreements for the purchase and...
December 12, 2023
By Dean Seal Shares of Aditxt and Evofem Biosciences soared after the companies signed a $100 million acquisition deal. Aditxt's stock was up 85% at $7.03 in...
September 10, 2023
Aditxt (NASDAQ:ADTX – Free Report) had its price objective increased by HC Wainwright to $61.00 in a research report sent to investors on Wednesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Aditxt’s Q3 2023 earnings at ($7.98) EPS, Q4 2023 earnings at ($4.47) […]
September 1, 2023
By Dean Seal Shares of Aditxt sank in premarket trading Friday after the company priced its private placement for proceeds of $10 million. The stock lost 44%...
September 1, 2023
Shares of Aditxt, Inc. (ADTX) are down more than 44 percent on Friday morning trade after the company decided to privately place 1,000,000 shares of $10 each amounting to $10 million.
May 5, 2023
Adimune, Inc. is nearing completion of its pre-clinical package for the immunotherapy clinical study drug candidate ADI-100 Collaboration will initially target Stiff Person Syndrome, a rare,... | May 5, 2023